Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vecuronium Bromide

FDA-approved product (injectable, injection), marketed as Norcuron, Vecuronium Bromide.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Vecuronium Bromide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Vecuronium Bromide. Its therapeutic class is shown instead.

WHO therapeutic group
Other quaternary ammonium compounds
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli31.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis42.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vecuronium Bromide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-3.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vecuronium Bromide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke

    NCT03263117 · start 2018-07-01

    Registered record
    Registry ID
    NCT03263117
    Conditions
    Stroke
    Interventions
    Sedation; General Anesthesia (GA); Intra-arterial Thrombectomy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-07-01
    Completion
    2023-04-22
    Enrolment
    260

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStroke
    InterventionSedation; General Anesthesia (GA); Intra-arterial Thrombectomy
    PhasePhase 4
    Registry statusCompleted

  • Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS

    NCT03376854 · start 2018-05-01

    Registered record
    Registry ID
    NCT03376854
    Conditions
    Respiratory Distress Syndrome, Adult; Sars-CoV2
    Interventions
    Hypothermia; Neuromuscular Blocking Agents; Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2018-05-01
    Completion
    2021-04-27
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRespiratory Distress Syndrome, Adult; Sars-CoV2
    InterventionHypothermia; Neuromuscular Blocking Agents; Standard of Care
    PhasePhase 2
    Registry statusWithdrawn

  • Effects of Hypotensive Anesthesia on Thiol Disulphide Balance

    NCT03501563 · start 2018-04-05

    Registered record
    Registry ID
    NCT03501563
    Conditions
    Nasal Septum Deviation
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-04-05
    Completion
    2018-12-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNasal Septum Deviation
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

    NCT03351608 · start 2018-02-12

    Registered record
    Registry ID
    NCT03351608
    Conditions
    Neuromuscular Blockade
    Interventions
    Sugammadex 2 mg/kg; Sugammadex 4 mg/kg; Neostigmine + Glycopyrrolate; Neostigmine + Atropine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-02-12
    Completion
    2020-01-28
    Enrolment
    288

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuromuscular Blockade
    InterventionSugammadex 2 mg/kg; Sugammadex 4 mg/kg; Neostigmine + Glycopyrrolate; Neostigmine + Atropine
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)

    NCT03346070 · start 2018-01-01

    Registered record
    Registry ID
    NCT03346070
    Conditions
    Neuromuscular Blockade
    Interventions
    Sugammadex 2 mg/kg ABW; Sugammadex 2 mg/kg IBW; Sugammadex 4 mg/kg ABW; Sugammadex 4 mg/kg IBW; Neostigmine + Glycopyrrolate; Rocuronium or Vecuronium
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-01-01
    Completion
    2019-01-29
    Enrolment
    207

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuromuscular Blockade
    InterventionSugammadex 2 mg/kg ABW; Sugammadex 2 mg/kg IBW; Sugammadex 4 mg/kg ABW; Sugammadex 4 mg/kg IBW +2 more
    PhasePhase 4
    Registry statusCompleted

  • Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

    NCT03346057 · start 2017-12-20

    Registered record
    Registry ID
    NCT03346057
    Conditions
    Reversal of Neuromuscular Blockade
    Interventions
    Sugammadex 2 mg/kg; Sugammadex 4 mg/kg; Sugammadex 16 mg/kg; Neostigmine + Glycopyrrolate; Rocuronium; Vecuronium
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-12-20
    Completion
    2019-09-04
    Enrolment
    344

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionReversal of Neuromuscular Blockade
    InterventionSugammadex 2 mg/kg; Sugammadex 4 mg/kg; Sugammadex 16 mg/kg; Neostigmine + Glycopyrrolate +2 more
    PhasePhase 4
    Registry statusCompleted

  • Evaluation of Atracurium-vecuronium Combination in Laparosocpic Surgery

    NCT03371953 · start 2017-12-20

    Registered record
    Registry ID
    NCT03371953
    Conditions
    Patients Undergoing Laparoscopic Surgery
    Interventions
    Vecuronium; Atracurium; Vecuronium + Atracurium
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-12-20
    Completion
    2018-10-25
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatients Undergoing Laparoscopic Surgery
    InterventionVecuronium; Atracurium; Vecuronium + Atracurium
    PhasePhase 4
    Registry statusUnknown

  • Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient

    NCT03196791 · start 2017-10-10

    Registered record
    Registry ID
    NCT03196791
    Conditions
    Gastric Cancer; Obesity
    Interventions
    Sugammadex Sodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-10-10
    Completion
    2020-09-09
    Enrolment
    196

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Cancer; Obesity
    InterventionSugammadex Sodium
    PhasePhase 3
    Registry statusCompleted

  • Does Deep Neuromuscular Blockade Improve Operating Conditions During Total Hip Replacements?

    NCT03219294 · start 2017-05-01

    Registered record
    Registry ID
    NCT03219294
    Conditions
    Arthropathy of Hip
    Interventions
    Vecuronium 0.1 mg/kg; Vecuronium 0.2mg/kg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-05-01
    Completion
    2018-05-01
    Enrolment
    116

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArthropathy of Hip
    InterventionVecuronium 0.1 mg/kg; Vecuronium 0.2mg/kg
    PhasePhase 4
    Registry statusCompleted

  • Opioid-Free Shoulder Arthroplasty

    NCT03540030 · start 2016-09

    Registered record
    Registry ID
    NCT03540030
    Conditions
    Opioid Use; Shoulder Osteoarthritis; Avascular Necrosis; Rotator Cuff Tear; Arthritis; Inflammatory
    Interventions
    Gabapentin; Celecoxib; toradol; acetaminophen; regional block; propofol; IV lidocaine; rocuronium; vecuronium; sevoflurane; desflurane
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-09
    Completion
    2019-06
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Use; Shoulder Osteoarthritis; Avascular Necrosis; Rotator Cuff Tear +2 more
    InterventionGabapentin; Celecoxib; toradol; acetaminophen +7 more
    PhasePhase 4
    Registry statusCompleted

  • Studies of Application of Combined General Anesthesia and Bilateral TPVB in OPCABG

    NCT02727712 · start 2016-04

    Registered record
    Registry ID
    NCT02727712
    Conditions
    Coronary Heart Disease
    Interventions
    bilateral thoracic paravertebral block; Transesophageal Echocardiography（TEE）; Lung protection measure during the surgery（Dräger Primus）; Anesthesia drugs during the surgery; thoracic paravertebral block
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2016-04
    Completion
    2016-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Heart Disease
    Interventionbilateral thoracic paravertebral block; Transesophageal Echocardiography（TEE）; Lung protection measure during the surgery（Dräger Primus）; Anesthesia drugs during the surgery +1 more
    PhasePhase 4
    Registry statusUnknown

  • Comparison of Leg Elevation and Leg Wrapping in the Prevention of Propofol Induced Hypotension

    NCT02845921 · start 2016-01

    Registered record
    Registry ID
    NCT02845921
    Conditions
    Propofol Induced Hypotension
    Interventions
    leg elevation; leg wrapping; control
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2016-01
    Completion
    2017-12
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPropofol Induced Hypotension
    Interventionleg elevation; leg wrapping; control
    PhaseNot applicable
    Registry statusUnknown

  • Dexmedetomidine Affect Diabetic Patient's Glucose Metabolism

    NCT02510612 · start 2015-08

    Registered record
    Registry ID
    NCT02510612
    Conditions
    Diabetes
    Interventions
    Dexmedetomidine; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-08
    Completion
    2016-12
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes
    InterventionDexmedetomidine; placebo
    PhasePhase 4
    Registry statusUnknown

  • The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS)Applied on Cardiac Surgery With Cardiopulmonary Bypass

    NCT02479581 · start 2015-07

    Registered record
    Registry ID
    NCT02479581
    Conditions
    Valvular Heart Disease
    Interventions
    ERAS group; ERAS group; ERAS group; ERAS group; ERAS group; ERAS group; ERAS group; ERAS group; ERAS group; ERAS group; ERAS group; ERAS group; Conventional control group; ERAS group; Conventional control group; Conventional control group; Conventional control group; Conventional control group; Conventional control group; Conventional control group
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-07
    Completion
    2017-05
    Enrolment
    226

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionValvular Heart Disease
    InterventionERAS group; ERAS group; ERAS group; ERAS group +16 more
    PhasePhase 2
    Registry statusCompleted

  • Intraoperative Lidocaine Infusion vs. Esmolol Infusion for Postoperative Analgesia in Laparoscopic Cholecystectomy

    NCT02327923 · start 2015-01

    Registered record
    Registry ID
    NCT02327923
    Conditions
    Gall Stone Disease
    Interventions
    Lidocaine; Esmolol; Paracetamol; Lidocaine; Propofol; Fentanyl; Vecuronium; Atropine; Ephedrine; Morphine; Ketorolac; Ondansetron; Bupivacaine; Tramadol; Neostigmine; Glycopyrrolate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-01
    Completion
    2016-04
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGall Stone Disease
    InterventionLidocaine; Esmolol; Paracetamol; Lidocaine +12 more
    PhasePhase 4
    Registry statusCompleted